


Amendments to the Claims

Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound having the formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 or 6 membered heteroaromatic ring containing 1 or 2 nitrogen ring atoms, thiazolyl, or thiadiazolyl, wherein the NH is linked to a carbon ortho to a nitrogen on the HetAr ring;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, fluoro, chloro, bromo, or iodo;

A is a bond or -C₁₋₂alkyl-; and

B is aryl(CH₂)₀₋₃-O-C(O)-, indanyl(CH₂)₀₋₃-O-C(O)-, aryl(CH₂)₁₋₃-C(O)-, aryl-cyclopropyl-C(O)-, aryl(CH₂)₁₋₃-NH-C(O)-, wherein any of the aryl is optionally substituted by 1-5 substituents, each substituent independently is C₁₋₄alkyl, fluoro, or chloro.

2. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom.

3. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms.

4. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl.

5. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiadiazolyl.

6. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is 1,2,4 thiadiazolyl.

7. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is a bond.

8. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is methylene.

9. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

A is $-C_2$ alkyl-.

10. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

B is aryl-cyclopropyl-C(O)-, wherein said aryl is optionally substituted as defined in Claim 1.

11. (Original) The compound according to Claim 10, or a pharmaceutically acceptable salt thereof, wherein said aryl is phenyl, optionally substituted as defined in Claim 1.

12. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein
B is aryl(CH₂)₀₋₃-O-C(O)-, wherein said aryl is optionally substituted as defined in Claim 1.

13. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salts thereof, wherein
B is aryl(CH₂)-O-C(O)-, wherein said aryl is optionally substituted as defined in Claim 1.

14. (Original) The compound according to Claim 13, or a pharmaceutically acceptable salt thereof, wherein said aryl is optionally substituted with C₁₋₄ alkyl.

15. (Original) The compound according to Claim 14, or a pharmaceutically acceptable salt thereof, wherein said aryl is 4-tolyl.

16. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein
HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;
A is methylene; and
B is aryl(CH₂)-O-C(O)-, wherein said aryl is optionally substituted as defined in Claim 1.

17. (Original) The compound according to Claim 16, or a pharmaceutically acceptable salt thereof, wherein
said aryl is optionally substituted with C₁₋₄ alkyl.

18. (Original) The compound according to Claim 17, or a pharmaceutically acceptable salt thereof, wherein
said aryl is 4-tolyl.

19. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

A is methylene; and

B is 4-tolyl(CH₂)–O–C(O)–.

20. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiadiazolyl;

A is methylene; and

B is aryl(CH₂)–O–C(O)–, wherein said aryl is optionally substituted as defined in Claim

1.

21. (Original) The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

HetAr is 1,2,4-thiadiazolyl;

A is methylene; and

B is 4-tolyl(CH₂)–O–C(O)–.

22. (Original) The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

A is methylene; and


B is aryl-cyclopropyl-C(O)–.

23. (Original) The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; and


B is phenyl-cyclopropyl-C(O)–.

24. (Original) The compound according to Claim 1, wherein said compound is




or a pharmaceutically acceptable salt thereof.

25. (Original) The compound according to Claim 1, wherein said compound is




or a pharmaceutically acceptable salt thereof.

26. (Original) The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.


27. (Original) The compound according to Claim 1, wherein said compound is



(-)

or a pharmaceutically acceptable salt thereof.


28. (Original) The compound according to Claim 1, wherein said compound is



(+)


or a pharmaceutically acceptable salt thereof.

29. (Original) The compound according to Claim 1, wherein said compound is




or a pharmaceutically acceptable salt thereof.

30. (Original) The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

31. (Original) The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

32. (Original) A pharmaceutical composition comprising an inert carrier and a therapeutically effective amount of a compound according to Claim 1.

- 33-46. (Canceled)